SERUM ERYTHROPOIETIN LEVEL CORRELATED WITH MICROALBUMINURIA IN DIABETIC PATIENTS
Abstract
Erythropoietin has beneficial effects in diabetic nephropathy, neuropathy and retinopathy. We investigated the relationship between iron indices and erythropoietin levels in type 2 diabetics with microvascular complications. Type 2 diabetic patients with microalbuminuria, diabetic retinopathy (DRP) and neuropathy were included to the present study. Serum erythropoietin levels and iron indices were recorded besides demographic, clinic and biochemical data. Of the 59 patients included in this study, microalbuminuria was present in 29 patients (49.2 %), while DRP and diabetic neuropathy were detected in 23 (39.7%) and 20 (34.5%) patients, respectively. Erythropoietin concentration (13.17±4.48 mU/mL vs 15.77±5.16 mU/mL; p=0.04) and total iron binding capacity (TIBC) of the microalbuminuric group were lower than those without microalbuminuria, while iron levels were similar. Erythropoietin concentration was lower in patients with DRP compared to those without DRP (12.84±4.95 mU/mL vs 15.49±4.82 mU/mL; p=0.04). TIBC was higher in patients with diabetic neuropathy; while erythropoietin (13.93±4.83 mU/mL vs. 14.71±5.13 mU/mL; p=0.57), ferritin and iron levels were similar to patients without neuropathy. Lower erythropoietin concentrations observed in patients with DRP and neuropathy are consistent with the hypothesis that erythropoietin deficiency may precede microvascular complications in diabetic patients. Serum erythropoietin level was found to correlate with microalbuminuria (p: 0.006, r:-0.50) but not retinopathy and neuropathy.
Downloads
References
2. Canturk Z, Cetinarslan B, Tarkun I, Canturk NZ. Serum ferritin levels in poorly- and well-controlled diabetes mellitus. Endocr Res 2003;29(3):299-306.
3. Yu FJ, Huang MC, Chang WT, et al. Increased Ferritin Concentrations Correlate with Insulin Resistance in Female Type 2 Diabetic Patients. Ann Nutr Metab 2012;61(1):32-40.
4. Tajima S, Ikeda Y, Sawada K, et al. Iron reduction by deferoxamine leads to amelioration of adiposity via the regulation of oxidative stress and inflammation in obese and type 2 diabetes KKAy mice. Am J Physiol Endocrinol Metab 2012;302(1):77-86.
5. Hernández C, Simó R. Erythropoietin produced by the retina: its role in physiology and diabetic retinopathy. Endocrine 2012;41(2):220-226.
6. Liu Q, Sun L, Tan Y, Wang G, Lin X, Cai L. Role of iron deficiency and overload in the pathogenesis of diabetes and diabetic complications. Current Medicinal Chemistry 2009;16:113-129.
7. Doggrell SA. A neuroprotective derivative of erythropoietin that is not erythropoietic. Expert Opin Investig Drugs. 2004; 13(11):1517-1519.
8. Spallone V, Maiello MR, Kurukulasuriya N, et al. Does autonomic neuropathy play a role in erythropoietin regulation in non-proteinuric Type 2 diabetic patients?
Diabet Med 2004;21(11):1174-1180.
9. Schmidt RE, Green KG, Feng D, et al. Erythropoietin and its carbamylated derivative prevent the development of experimental diabetic autonomic neuropathy in STZ-induced diabetic NOD-SCID mice. Exp Neurol 2008;209(1):161-170.
10. Symeonidis A, Kouraklis-Symeonidis A, Psiroyiannis A, et al. Inappropriately low erythropoietin response for the degree of anemia in patients with noninsulin-dependent diabetes mellitus. Ann Hematol 2006;85:79-85.
11. Maiese K. Erythropoietin and diabetes mellitus. World J Diabetes 2015 Oct 25;6(14):1259-73. doi: 10.4239/wjd.v6.i14.1259
12. Bosman DR, Winkler AS, Marsden JT, Macdougall IC, Watkins PJ. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 2001;24(3):495-499.
13. Mojiminiyi OA, Abdella NA, Zaki MY, El Gebely SA, Mohamedi HM, Aldhahi WA. Prevalence and associations of low plasma erythropoietin in patients with
Type 2 diabetes mellitus. Diabetic Medicine 2006;23:839-844.
14. Cosimo M, Brunoa T, Sciaccaa C, et al. Circulating erythropoietin in microalbuminuric type 2 diabetic patients with normal renal function: a pilot study. J Diabetes Complications 2006;20:376-379.
15. Singh DK, Winocour P, Summerhayes B, Viljoen A, Sivakumar G, Farrington K. Are low erythropoietin and 1,25-dihydroxyvitamin D levels indicative of tubulo-interstitial dysfunction in diabetes without persistent microalbuminuria? Diabetes Res Clin Pract 2009;85(3):258-264.
16. Ronald G Pearl. Erythropoietin and organ protection: lessons from negative clinical trials. Crit Care 2014; 18(5): 526.
17. Said G, Lacroix C, Lozeron P, Ropert A, Planté V, Adams D. Inflammatory vasculopathy in multifocal diabetic neuropathy. Brain 2003;126(Pt 2):376-385.
18. Bartnicki P, Kowalczyk M, Rysz J. The influence of the pleiotropic action of erythropoietin and its derivatives on nephroprotection. Med Sci Monit 2013;22 (19): 599-605.
19. Iwasaki T, Nakajima A, Yoneda M, et al. Serum ferritin is associated with visceral fat area and subcutaneous fat area. Diabetes Care 2005;28(10):2486-2491.
20. Gillum RF. Association of serum ferritin and indices of body fat distribution and obesity in Mexican American men: the Third National Health and Nutrition
Examination Survey. Int J Obes Relat Metab Disord 2001;25(5):639-645.
21. Fernandez-Real JM, Ricart-Engel W, Arroyo E, et al. Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care 1998;21:62-68.
22. Gradinaru D, Margina D, Ilie M, Borsa C, Ionescu C, Prada GI. Correlation between erythropoietin serum levels and erythrocyte susceptibility to lipid peroxidation in elderly with type 2 diabetes. Acta Physiol Hung 2015; 102 (4): 400-8.
